Avid Radiopharmaceuticals Presents at J.P. Morgan Investor Conference
Posted by | January 21, 2010
Safeguard Scientifics’ partner company Avid Radiopharmaceuticals was invited to present its technology and growth strategy at the prestigious J.P. Morgan 28th Annual Healthcare Conference in San Francisco in mid-January.
Avid founder and CEO Daniel M. Skovronsky, M.D., Ph.D. is leading the teams that are developing molecular imaging products to enable early diagnosis and prognosis of brain disorders, specifically Alzheimer’s and Parkinson’s diseases.
Avid remains on track with FDA Phase III trials of its lead compound, 18F florbetapir which binds to amyloid plaques in the brain to image Alzheimer’s disease, an addressable market estimated at more than $500 million annually. An NDA submission is anticipated in 2010. Avid’s 18F-AV-133 imaging compound for the detection of Parkinson’s disease is currently in Phase II trials, while its compound for imaging diabetes is currently in proof of concept Phase I trials.
